Black FridayUp to 80% OFF
Cybin, Inc.Cybin, Inc.Cybin, Inc.

Cybin, Inc.

No trades
See on Supercharts
OverviewFinancialsNewsDocumentsIdeasMindsTechnicalsForecastsSeasonalsETFs

Chart


Full chart

Upcoming earnings


Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪414.62 M‬ CAD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−5.43 CAD
Net income (FY)
‪−113.14 M‬ CAD
Revenue (FY)
0.00 CAD
Shares float
‪38.09 M‬
Beta (1Y)
—

Employees


Employees (FY)
50
Revenue / Employee (1Y)
0.00 CAD
Net income / Employee (1Y)
‪−2.26 M‬ CAD

About Cybin, Inc.


Sector
Health Technology
Industry
Pharmaceuticals: Major
CEO
Eric So
Website
cybin.com
Headquarters
Toronto
Founded
2016
ISIN
CA23256X4075
FIGI
BBG00HZ0NHX4
Cybin, Inc. operates as a clinical-stage biopharmaceutical company on a mission to create safe and effective psychedelic-based therapeutics to address the large unmet need for new and innovative treatment options for people who suffer from mental health conditions. It is currently developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder and CYB004, a proprietary deuterated DMT molecule for generalized anxiety disorder and has a research pipeline of investigational psychedelic-based compounds. The company was founded by Paul Glavine, Eric So, and John Kanakis on October 13, 2016 and is headquartered in Toronto, Canada.

Check out other big names from the same industry as CYBN.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

News



Ideas



See all ideas 

Technicals


Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

ETFs


PSIL
AdvisorShares Psychedelics ETF
Weight
5.37%
Market value
‪935.89 K‬
USD
IBB
iShares Biotechnology ETF
Weight
0.01%
Market value
‪926.96 K‬
USD
TMED
T. Rowe Price Health Care ETF
Weight
0.15%
Market value
‪21.43 K‬
USD

Explore more ETFs 

Frequently Asked Questions


The current price of CYBN is 7.98 CAD — it has decreased by −3.73% in the past 24 hours. Watch Cybin, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NEO exchange Cybin, Inc. stocks are traded under the ticker CYBN.
CYBN stock has fallen by −2.44% compared to the previous week, the month change is a −4.76% fall, over the last year Cybin, Inc. has showed a −50.13% decrease.
We've gathered analysts' opinions on Cybin, Inc. future price: according to them, CYBN price has a max estimate of 79.86 CAD and a min estimate of 42.03 CAD. Watch CYBN chart and read a more detailed Cybin, Inc. stock forecast: see what analysts think of Cybin, Inc. and suggest that you do with its stocks.
CYBN reached its all-time high on Jul 27, 2021 with the price of 152.00 CAD, and its all-time low was 6.95 CAD and was reached on Apr 9, 2025. View more price dynamics on CYBN chart.
See other stocks reaching their highest and lowest prices.
Yes, you can track Cybin, Inc. financials in yearly and quarterly reports right on TradingView.
Cybin, Inc. is going to release the next earnings report on Feb 17, 2026. Keep track of upcoming events with our Earnings Calendar.
CYBN earnings for the last quarter are −1.95 CAD per share, whereas the estimation was −1.46 CAD resulting in a −33.83% surprise. The estimated earnings for the next quarter are −1.06 CAD per share. See more details about Cybin, Inc. earnings.
Cybin, Inc. revenue for the last quarter amounts to 0.00 CAD, matching the estimated figure, and no changes in revenue are expected for the next quarter.
CYBN net income for the last quarter is ‪−46.45 M‬ CAD, while the quarter before that showed ‪−34.06 M‬ CAD of net income which accounts for −36.36% change. Track more Cybin, Inc. financial stats to get the full picture.
No, CYBN doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 22, 2025, the company has 50 employees. See our rating of the largest employees — is Cybin, Inc. on this list?
Like other stocks, CYBN shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Cybin, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Cybin, Inc. technincal analysis shows the strong sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Cybin, Inc. stock shows the sell signal. See more of Cybin, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.